Cargando…

A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges

BACKGROUND: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far...

Descripción completa

Detalles Bibliográficos
Autores principales: Kissling, Sébastien, Legallais, Cécile, Pruijm, Menno, Teta, Daniel, Vogt, Bruno, Burnier, Michel, Rondeau, Eric, Ridel, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333425/
https://www.ncbi.nlm.nih.gov/pubmed/28249613
http://dx.doi.org/10.1186/s12882-017-0494-9
_version_ 1782511705701482496
author Kissling, Sébastien
Legallais, Cécile
Pruijm, Menno
Teta, Daniel
Vogt, Bruno
Burnier, Michel
Rondeau, Eric
Ridel, Christophe
author_facet Kissling, Sébastien
Legallais, Cécile
Pruijm, Menno
Teta, Daniel
Vogt, Bruno
Burnier, Michel
Rondeau, Eric
Ridel, Christophe
author_sort Kissling, Sébastien
collection PubMed
description BACKGROUND: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far. The objective of this study was to assess the determinants of blood citrate concentration needed and to develop an individualized RCA protocol useful for clinical practice. METHODS: The study population included 14 patients who underwent a total of 47 TPE sessions. Citrate was infused pre-plasmafilter. Post-plasmafilter and systemic plasma ionized calcium concentrations were measured at standardized time intervals. An algorithm was proposed for the supplementation of calcium. During the discovery phase, citrate was infused at a fixed starting rate, and adapted accordingly to obtained post-plasmafilter ionized calcium levels. Using a mathematical approach, an algorithm was thereafter developed for individualized prescriptions of citrate. RESULTS: Pre-treatment values of hematocrit and plasma ionized calcium were the main determinants of the required rate of citrate infusion. These can be integrated into a final equation enabling to individualize the prescription. A prefilter ionized calcium concentration between 0.24 and 0.33 mmol/l prevented coagulation of the extracorporeal circuit. Significant hypocalcemia occurred in 8.5% of treatments. There were no significant acid–base disturbances. CONCLUSION: We propose a new protocol, which enables for the first time to individualize the prescription of regional citrate anticoagulation during TPE, in an efficient manner. The immediately obtained regional anticoagulation protects against both the risk of coagulation of the membrane and the exposure to an excess of citrate. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0494-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5333425
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53334252017-03-06 A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges Kissling, Sébastien Legallais, Cécile Pruijm, Menno Teta, Daniel Vogt, Bruno Burnier, Michel Rondeau, Eric Ridel, Christophe BMC Nephrol Technical Advance BACKGROUND: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment protocol has been proposed for therapeutic plasma exchange (TPE) so far. The objective of this study was to assess the determinants of blood citrate concentration needed and to develop an individualized RCA protocol useful for clinical practice. METHODS: The study population included 14 patients who underwent a total of 47 TPE sessions. Citrate was infused pre-plasmafilter. Post-plasmafilter and systemic plasma ionized calcium concentrations were measured at standardized time intervals. An algorithm was proposed for the supplementation of calcium. During the discovery phase, citrate was infused at a fixed starting rate, and adapted accordingly to obtained post-plasmafilter ionized calcium levels. Using a mathematical approach, an algorithm was thereafter developed for individualized prescriptions of citrate. RESULTS: Pre-treatment values of hematocrit and plasma ionized calcium were the main determinants of the required rate of citrate infusion. These can be integrated into a final equation enabling to individualize the prescription. A prefilter ionized calcium concentration between 0.24 and 0.33 mmol/l prevented coagulation of the extracorporeal circuit. Significant hypocalcemia occurred in 8.5% of treatments. There were no significant acid–base disturbances. CONCLUSION: We propose a new protocol, which enables for the first time to individualize the prescription of regional citrate anticoagulation during TPE, in an efficient manner. The immediately obtained regional anticoagulation protects against both the risk of coagulation of the membrane and the exposure to an excess of citrate. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0494-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-03-01 /pmc/articles/PMC5333425/ /pubmed/28249613 http://dx.doi.org/10.1186/s12882-017-0494-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Technical Advance
Kissling, Sébastien
Legallais, Cécile
Pruijm, Menno
Teta, Daniel
Vogt, Bruno
Burnier, Michel
Rondeau, Eric
Ridel, Christophe
A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
title A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
title_full A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
title_fullStr A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
title_full_unstemmed A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
title_short A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
title_sort new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333425/
https://www.ncbi.nlm.nih.gov/pubmed/28249613
http://dx.doi.org/10.1186/s12882-017-0494-9
work_keys_str_mv AT kisslingsebastien anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT legallaiscecile anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT pruijmmenno anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT tetadaniel anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT vogtbruno anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT burniermichel anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT rondeaueric anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT ridelchristophe anewprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT kisslingsebastien newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT legallaiscecile newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT pruijmmenno newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT tetadaniel newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT vogtbruno newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT burniermichel newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT rondeaueric newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges
AT ridelchristophe newprescriptionmodelforregionalcitrateanticoagulationintherapeuticplasmaexchanges